Pengpid Supa, Peltzer Karl
Department of Health Education and Behavioral Sciences, Faculty of Public Health, Mahidol University, Bangkok, Thailand.
Department of Psychology, University of the Free State, Bloemfontein, South Africa.
Prev Med Rep. 2022 Jun 27;28:101874. doi: 10.1016/j.pmedr.2022.101874. eCollection 2022 Aug.
Dyslipidaemia is increasing with low awareness and treatment in low resourced countries. The aim of the study was to evaluate the prevalence, distribution, and correlates of dyslipidaemia and its awareness, treatment, and control among people (18-69 years) in Jordan. In a national cross-sectional survey, a total of 3,132 individuals (mean age: 41.7 years) that took part in the Jordan cross-sectional STEPS survey in 2019 and had complete lipid measurements. Dyslipidemia was defined using the guidelines of the Adult Treatment Panel III. The prevalence of dyslipidemia was 81.6%, 74.0% low high-density lipoprotein cholesterol (HDL-C), 28.2% high triglyceride (TG), 10.1% high total cholesterol (TC) and 8.7% high low-density lipoprotein cholesterol (LDL-C). Among those with dyslipidaemia, 9.3% were aware. Among those who knew, the proportion of lipid-lowering drug treatment was 50.3%, and among those taking lipid-lowering drugs, 25.4% had their dyslipidaemia controlled. In adjusted logistic regression, in both sexes, overweight (AOR: 2.14, 95% CI: 1.49-3.36), obesity (AOR: 2.47, 95% CI: 1.55-3.94), diabetes (AOR: 2.63, 95% CI: 1.30-5.34) were positively and moderate physical activity (AOR: 0.60, 95% CI: 0.37-0.95) was negatively associated with prevalence of dyslipidemia. Older age, overweight, obesity, hypertension, diabetes, and cardiovascular disease were positively associated, and moderate physical activity was negatively associated with awareness of dyslipidemia. Four out of five adults in Jordan had dyslipidaemia and less than one in ten were aware. Several factors associated with the prevalence, awareness, and treatment of dyslipidaemia were identified that can be used to target public health interventions.
在资源匮乏的国家，血脂异常的情况日益增多，且人们对其认知和治疗水平较低。本研究旨在评估约旦18至69岁人群中血脂异常的患病率、分布情况及其相关因素，以及血脂异常的知晓率、治疗率和控制率。在一项全国性横断面调查中，共有3132名个体（平均年龄：41.7岁）参与了2019年约旦横断面的“行为危险因素监测系统（STEPS）”调查，且进行了完整的血脂测量。血脂异常根据成人治疗专家组第三次报告的指南进行定义。血脂异常的患病率为81.6%，其中低密度脂蛋白胆固醇（HDL-C）水平低的患病率为74.0%，高甘油三酯（TG）的患病率为28.2%，高总胆固醇（TC）的患病率为10.1%，高低密度脂蛋白胆固醇（LDL-C）的患病率为8.7%。在血脂异常患者中，知晓率为9.3%。在知晓自己患病的人群中，接受降脂药物治疗的比例为50.3%，而在服用降脂药物的人群中，血脂异常得到控制的比例为25.4%。在调整后的逻辑回归分析中，无论男女，超重（比值比[AOR]：2.14，95%置信区间[CI]：1.49 - 3.36）、肥胖（AOR：2.47，95% CI：1.55 - 3.94）、糖尿病（AOR：2.63，95% CI：1.30 - 5.34）与血脂异常患病率呈正相关，而适度体育活动（AOR：0.60，95% CI：0.37 - 0.95）与血脂异常患病率呈负相关。年龄较大、超重、肥胖、高血压、糖尿病和心血管疾病与血脂异常知晓率呈正相关，而适度体育活动与血脂异常知晓率呈负相关。约旦五分之四的成年人患有血脂异常，且每十人中知晓自己患病的不到一人。研究确定了一些与血脂异常的患病率、知晓率和治疗相关的因素，可用于指导公共卫生干预措施。
